Lantern Pharma Inc (LTRN): Rasio rega marang pendapatan

Lantern Pharma Inc. (LTRN) merges IT and medicine by utilizing the RADR AI system to match therapies with the genetics of lung cancer patients. The company has outsourced production and testing to third-party contractors to minimize costs. The company's P/S ratio reflects market expectations, where the level indicates the status of the parameter. The potential for business value growth is based on the B2B licensing of its predictive platform to other biopharma companies.

The P/S ratio depends directly on operating revenue, excluding the impact of accounting depreciation. This metric compares the market value of a business with its annual sales volume to determine the extent of the asset's overvaluation. For Lantern Pharma Inc. (LTRN), this indicator reflects the monetization of its AI platform through partnerships prior to the emergence of mass clinical data. Analyzing the price-to-sales chart allows for the timely detection of company overvaluation.